Hahn Capital Management LLC Decreases Stock Holdings in Becton, Dickinson and Company $BDX

Hahn Capital Management LLC lowered its stake in Becton, Dickinson and Company (NYSE:BDX) by 9.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,748 shares of the medical instruments supplier’s stock after selling 2,819 shares during the period. Becton, Dickinson and Company makes up approximately 3.1% of Hahn Capital Management LLC’s investment portfolio, making the stock its 17th biggest position. Hahn Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $6,356,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Saudi Central Bank purchased a new position in shares of Becton, Dickinson and Company during the 1st quarter worth about $26,000. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth $27,000. REAP Financial Group LLC raised its stake in Becton, Dickinson and Company by 75.3% in the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 55 shares in the last quarter. Alpine Bank Wealth Management bought a new stake in Becton, Dickinson and Company during the first quarter valued at about $29,000. Finally, Cornerstone Planning Group LLC boosted its stake in Becton, Dickinson and Company by 341.4% in the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 99 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on BDX shares. Citigroup cut shares of Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and reduced their target price for the stock from $217.00 to $185.00 in a report on Thursday, May 22nd. Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Morgan Stanley boosted their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Piper Sandler restated a “neutral” rating and issued a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Finally, Barclays lowered their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating for the company in a research report on Tuesday, June 3rd. Four investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $211.44.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $190.52 on Friday. The stock has a market capitalization of $54.61 billion, a PE ratio of 34.27, a price-to-earnings-growth ratio of 1.41 and a beta of 0.27. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The business has a 50 day simple moving average of $186.24 and a 200-day simple moving average of $192.03.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping analysts’ consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. During the same quarter in the prior year, the company posted $3.50 earnings per share. Becton, Dickinson and Company’s quarterly revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be issued a dividend of $1.04 per share. The ex-dividend date is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company’s payout ratio is 74.82%.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,185 shares of the business’s stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. The trade was a 19.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Claire Fraser sold 917 shares of the company’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares of the company’s stock, valued at $4,167,375. The trade was a 3.96% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 2,965 shares of company stock valued at $551,536 over the last quarter. 0.36% of the stock is currently owned by insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.